Defence Investigates the Application of the Accum Hydrogel Technology to Deliver GLP-1 in Order to Increase the Treatment Efficacy of Diabetes and Weight Loss

● . ● | --- | --- | |---------------------------------------------------|-------| | | | | Defence Investigates the Application of the Accum | | | Hydrogel Technology to Deliver GLP-1 in Order to | | | Increase the Treatment Efficacy of Diabetes and | | August 19, 2024 9:27 AM EDT | Source: Defence Therapeutics Inc. Vancouver, British Columbia--(Newsfile Corp. - August 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company ...